Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Short-term Investments (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Short-term Investments for 7 consecutive years, with $67.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 11.26% year-over-year to $67.9 million, compared with a TTM value of $67.9 million through Dec 2025, up 11.26%, and an annual FY2025 reading of $67.9 million, up 11.26% over the prior year.
  • Short-term Investments was $67.9 million for Q4 2025 at aTYR PHARMA, up from $63.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $105.6 million in Q4 2021 and bottomed at $38.0 million in Q1 2021.
  • Average Short-term Investments over 5 years is $70.9 million, with a median of $67.9 million recorded in 2025.
  • The sharpest move saw Short-term Investments soared 616.39% in 2021, then crashed 46.8% in 2022.
  • Year by year, Short-term Investments stood at $105.6 million in 2021, then plummeted by 46.8% to $56.2 million in 2022, then skyrocketed by 34.64% to $75.6 million in 2023, then fell by 19.24% to $61.1 million in 2024, then increased by 11.26% to $67.9 million in 2025.
  • Business Quant data shows Short-term Investments for ATYR at $67.9 million in Q4 2025, $63.1 million in Q2 2025, and $66.0 million in Q1 2025.